Biogen is hustling a schizophrenia drug into PhIIb after Pfizer lets it go in $590M CNS fire sale
Pfizer’s $PFE decision to beat a retreat from its pipeline of neurosciences drugs has triggered its first asset sale.
Biogen $BIIB is stepping up with $75 million in cash and committing up to $515 million in milestones to seal the deal on Pfizer’s schizophrenia drug PF-04958242. The drug has been through an early-stage study, and now Biogen will add it to a lean pipeline of CNS therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.